Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | PHASE2 | ACTIVE NOT_RECRUITING | 206 | — | — | Sep 23, 2021 | Dec 1, 2026 | Jan 9, 2026 | 68 | United States, Australia +7 |
Progression-free survival per RECISTv1.1 will be determined.
| Arm | Type | Description |
|---|---|---|
| INBRX-109 | EXPERIMENTAL | IV every three weeks |
| Placebo | PLACEBO_COMPARATOR | IV every three weeks |
| Name | Type | Description |
|---|---|---|
| INBRX-109 | DRUG | Tetravalent DR5 Agonist Antibody |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic. 2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously irradiated (or other locally treated) area will be considered measurable, provided there has been clear imaging-based progre...